<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318148</url>
  </required_header>
  <id_info>
    <org_study_id>UKW-Inf-001</org_study_id>
    <secondary_id>2009-015159-26</secondary_id>
    <nct_id>NCT01318148</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis</brief_title>
  <acronym>CASPHYLAX</acronym>
  <official_title>Prospective Trial to Evaluate Pharmacokinetic, Safety and Efficacy of Intermittent Application of Increased Doses of Caspofungin for Antifungal Prophylaxis in High Risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Werner J. Heinz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a pilot phase II, prospective, non-comparative, single center trial aimed to
      evaluate pharmacokinetic and safety of an intermittent dosing schedule for antifungal
      prophylaxis in high risk patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetic and safety of caspofungin, in an intermittent dosing schedule, for
      prophylaxis of invasive fungal (IFI) infections will be evaluated in patients receiving
      induction chemotherapy for treatment of acute myeloid leukemia, myelodysplastic syndrome with
      blast crisis or acute lymphatic leukemia.

      For prophylaxis caspofungin once daily will be given three times a week after a loading phase
      of three days. For drug monitoring serum samples will be collected from the first day of
      trial medication till one day after end of therapy (EOT). Invasive fungal infections will be
      diagnosed analog the criteria defined by the European organization for Research and Treatment
      of Cancer and the Mycosis Study Group (EORTC/MSG), revised in 2008.

      Caspofungin prophylaxis will be stopped after the end of neutropenia, in case of documented
      proven or probable invasive fungal disease and in case of a serious adverse event
      attributable to the study drug, for which in view of the investigator further usage of the
      study drug should be avoided.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>caspofungin pharmacokinetic</measure>
    <time_frame>day 20 (average), till end of enutropenia</time_frame>
    <description>To characterize the pharmacokinetic of caspofungin IV solution in an intermittent dosing schedule of 3 times a week after a 3 days loading in a representative subject population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caspofungin pharmacokinetic</measure>
    <time_frame>day 20 (average), at end of neutropenia</time_frame>
    <description>caspofungin serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive fungal disease and outcome</measure>
    <time_frame>day 100 after start of chemotherapy</time_frame>
    <description>Incidence of proven or probable invasive fungal disease according to the revised EORTC/MSG criteria during the period of prophylaxis and during follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of intermittent caspofungin</measure>
    <time_frame>day 34 (average), 2 weeks after end of neutropenia</time_frame>
    <description>Caspofungin related and all adverse and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Caspofungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caspofungin</intervention_name>
    <description>Intermittent intravenous application of caspofungin</description>
    <arm_group_label>Caspofungin</arm_group_label>
    <other_name>Cancidas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute myeloid leukemia or myelodysplastic syndrome and blast crisis or acute lymphatic
             leukemia

          -  receiving induction chemotherapy

        Exclusion Criteria:

          -  current or need of systemic antifungal therapy

          -  history of proven or probable invasive aspergillus infection

          -  pregnant or breastfeeding women

          -  weight more than 100 kg

          -  history of allergy, hypersensitivity or any serious reaction to caspofungin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner J Heinz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wuerzburg Medical Centre, Department of Internal Medicine II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wuerzburg Medical Centre, Department of Internal Medicine II</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wuerzburg University Hospital</investigator_affiliation>
    <investigator_full_name>Werner J. Heinz</investigator_full_name>
    <investigator_title>Consultant Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Echinocandins</keyword>
  <keyword>Caspofungin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Antifungal</keyword>
  <keyword>Aspergillosis</keyword>
  <keyword>Acute Leucemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

